Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03804489
Other study ID # 108HHC-03
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 25, 2019
Est. completion date December 25, 2019

Study information

Verified date January 2019
Source Taipei Medical University Shuang Ho Hospital
Contact Sheng-Chieh Lin, MD
Phone 886-2-2249-0088
Email jacklinmails@yahoo.com.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Using decision aids (DA) is one way to provide information to infant family and to involve them in making decisions about their baby's vaccination. We developed a DA administered after consultation for baby's family deciding on whether the baby will receive the self-paid oral rotavirus vaccine


Description:

Background:

Acute gastroenteritis is one of the most common infectious diseases and still a major cause of pediatric morbidity and mortality worldwide. Rotavirus was still the major cause of acute gastroenteritis in infants and young children worldwide, including in Taiwan. The World Health Organization has recommended rotavirus vaccine, which became available in 2006, for all countries. However, not all of children in Taiwan received rotavirus vaccination. Using decision aids (DA) is one way to provide information to infant family and to involve them in making decisions about their baby's vaccination. We developed a DA administered after consultation for baby's family deciding on whether the baby will receive the self-paid oral rotavirus vaccine Patients and Methods Decision aids are interventions designed to help infant family make choices among options by providing information relevant to oral rotavirus vaccine. Infant coming to receiving regular routine vaccination at 1 month old are randomly assigned to receive a DA or the standard oral conversation (control condition) after the initial consultation. Infant family complete interview-based questionnaires 1 month later when they came back to hospital receiving 2-month-old regular routine vaccination and decide to receive self-paid oral rotavirus vaccine or not at that time. Primary outcome measures: decisional conflict and decision-making difficulties at 2-month-old.

Results and Conclusion The DA group are predicted to lower decisional conflict scores when compared with the control group. Our study hopes to support the efficacy of DA in helping the infant family to decide whether the baby will receive the self-paid oral rotavirus vaccine.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 180
Est. completion date December 25, 2019
Est. primary completion date October 25, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

The one-month-old baby's family whose age is between 20 and 80 years old.

Exclusion Criteria:

1. . The doctor determines that the baby's family is not suitable; if baby's family cannot understand Chinese languages what we said.

2. . The participants' baby who have fever or contraindication for oral rotavirus.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Decision aids
Decision aids in helping the infant family to decide whether the infant will or will not receive the oral rotavirus vaccine.

Locations

Country Name City State
Taiwan Sheng-Chieh Lin New Taipei City No.291, Zhongzheng Road, Zhonghe District, New Taipei City

Sponsors (1)

Lead Sponsor Collaborator
Taipei Medical University Shuang Ho Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Decisional conflict Total score of decisional conflict scale An average of 1 month after intervention
Primary Decision-making difficulties Total score of decision-making scale An average of 1 month after intervention
See also
  Status Clinical Trial Phase
Completed NCT03207750 - This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine Phase 3
Completed NCT02914184 - Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks Phase 3
Completed NCT00241644 - Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants Phase 3
Completed NCT01733862 - Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis
Completed NCT00353366 - To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination
Unknown status NCT00669929 - Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea N/A
Completed NCT00432380 - A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants. Phase 2
Completed NCT05037435 - Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years. Phase 3
Completed NCT00480324 - Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants Phase 3
Completed NCT00595205 - Intussusception Surveillance After Rotarix Introduction in Mexico N/A
Completed NCT01177826 - Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children
Completed NCT00995813 - Pilot Study of the Rotavirus Vaccine in Infants With Intestinal Failure Phase 4
Completed NCT00969228 - Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants Phase 4